Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Levy (London, United Kingdom), H. Chrystyn (Leeds, United Kingdom), G. Safioti (Amsterdam, Netherlands), M. Depietro (West Chester, United States of America), R. Brown (West Chester, United States of America), T. Hill (West Chester, United States of America), L. Granovsky (Petah Tikva, Israel), M. Reich (Petah Tikva, Israel), S. Bosnic-Anticevich (Sydney, Australia). A digital inhaler uncovering patterns of SABA use in asthma and COPD. 1361

Member's Comments

No comment yet.

Related content which might interest you: SABA use increase weeks before asthma exacerbations recorded via a digital inhaler Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Description of the UK’s asthma and COPD inhaler use Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 The effect of inhaler switching on asthma and COPD patients Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018 Comparison of inhaler and nebuliser bronchodilator treatments in COPD attacks Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Source: Eur Respir J 2002; 19: 246-251 Year: 2002 Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Differences in inhaler misuse between patients with asthma and COPD. Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003 Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Preference of the inhaler device and assessment of the technique among the asthmatic and COPD patients Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Hair analysis to detect chronic inhaler drug use in asthma or COPD patients Source: International Congress 2017 – Monitoring novel biomarkers in asthma Year: 2017 Nighttime short-acting beta-agonist (SABA) in asthma and COPD Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019 Investigating inhaler technique in patients with COPD using different aids Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 COPD: Are beliefs about inhaled medication associated with patients’ inhaler technique? Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Comparing objective inhaler use among COPD and Asthma populations Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018 Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Preferences for current inhaler devices in patients with asthma Source: International Congress 2018 – Asthma and drugs Year: 2018 Cost-effectiveness of budesonid/formoterol inhaler in treatment of moderate bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006